Some of the worldâ€™s largest pharmaceutical companies are pooling resources to fund an ambitious genetic and medical database aimed at bolstering the search for new drugs.
AbbVie Inc., Alnylam Pharmaceuticals Inc., AstraZeneca PLC, Biogen Inc. and Pfizer Inc. will pay $10 million each to Regeneron Pharmaceuticals Inc., which began the project last year in partnership with the U.K. Biobank, a nonprofit that has collected DNA samples and health records from half a million people in the U.K., and drugmaker GlaxoSmithKline PLC.
... 